Report cover image

BlueRock Therapeutics LP - Strategic SWOT Spotlight

Publisher Quaintel Research
Published Sep 04, 2024
Length 44 Pages
SKU # QTELR19136191

Description

BlueRock Therapeutics LP - Strategic SWOT Spotlight


BlueRock Therapeutics LP - Strategic SWOT Spotlight is a comprehensive and easily accessible overview of The BlueRock Therapeutics LP's business operations. It provides a Snapshot of the company's position in the industry compared to competitors. The report includs key executives, products and services, ESG spotlight, Corporate Strategy, Business Description, Helicopter view of SWOT Analysis, Competitive Landscape and latest events.

Key Highlights

BlueRock Therapeutics, founded in 2016 and headquartered in Cambridge, Massachusetts, is a pioneering biotechnology company specializing in cell therapy. As a subsidiary of Bayer AG's Cell and Gene Therapy Platform, BlueRock focuses on developing transformative treatments for degenerative diseases by harnessing the potential of pluripotent stem cells (PSCs). The company has a global presence with operations also in Toronto, Canada, leveraging its proprietary technology to create and manufacture PSCs at scale. BlueRock Therapeutics is organized into distinct business segments, primarily focusing on neurology and ophthalmology. They have made significant strides in clinical research, including receiving FDA Regenerative Medicine Advanced Therapy designation for their Parkinson's disease cell therapy candidate, bemdaneprocel. This designation underscores their commitment to advancing innovative therapies that aim to replace damaged cells and restore function, potentially revolutionizing disease treatment paradigms worldwide.

BlueRock Therapeutics LP in the News:-
  • 30-May-2024 - BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson's disease cell therapy candidate bemdaneprocel
  • 25-Apr-2024 - Cell & Gene The Podcast: Inside BlueRock Therapeutics' Parkinson's Disease Trial
  • 25-Mar-2024 - BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases
  • 06-Mar-2024 - BlueRock Therapeutics phase I clinical trial for Parkinson's disease continues to show positive trends at 18 months
  • 23-Jan-2024 - BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics
Scope

Company Fundamentals:- These fundamentals offer valuable insights into BlueRock Therapeutics LP's operations, geographical presence, products and services, ESG spotlight, Corporate Strategy, Business Description and SWOT spotlight, aiding in a comprehensive understanding of the organization.

Reasons to Buy
  • Helicopter view of company's internal and external factors through SWOT analysis - Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers. - Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations. - Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Table of Contents

44 Pages
Table of Contents
Tables
Charts
BlueRock Therapeutics LP - Key Company Facts
BlueRock Therapeutics LP - Company Description
BlueRock Therapeutics LP - Top Executives
BlueRock Therapeutics LP - Head Office & Locations
Head Office - Country
BlueRock Therapeutics LP - Products and Services
Products
BlueRock Therapeutics LP - Corporate Strategy
BlueRock Therapeutics LP - Business Description
Neurology
Ophthalmology
BlueRock Therapeutics LP - ESG Spotlight
Environment
Social
Corporate Governance
BlueRock Therapeutics LP - SWOT Spotlight
Overview
Strengths
Weaknesses
Opportunities
Threats
Competing Players
Snapshot of Competing Players
Editas Medicine Inc.
Key Company Facts
Company Description
Key Financials:
Sangamo Therapeutics Inc.
Key Company Facts
Company Description
Key Financials:
Vertex Pharmaceuticals Incorporated
Key Company Facts
Company Description
Key Financials:
CRISPR Therapeutics AG
Key Company Facts
Company Description
Key Financials:
Intellia Therapeutics Inc
Key Company Facts
Company Description
Key Financials:
BlueRock Therapeutics LP - In the News
30-May-2024- BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson's disease cell therapy candidate bemdaneprocel
25-Apr-2024- Cell & Gene The Podcast: Inside BlueRock Therapeutics' Parkinson's Disease Trial
25-Mar-2024- BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases
06-Mar-2024- BlueRock Therapeutics phase I clinical trial for Parkinson's disease continues to show positive trends at 18 months
23-Jan-2024- BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics
Appendix
Definitions
SWOT Analysis
PESTLE Analysis
Value Chain Analysis
ESG Spotlight
Research Methodology
Disclaimer
Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us